467 related articles for article (PubMed ID: 28244067)
21. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
22. Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.
Harb J; Lin PJ; Hao J
Curr Oncol Rep; 2019 Feb; 21(2):12. PubMed ID: 30715618
[TBL] [Abstract][Full Text] [Related]
23. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities.
Liu J; Xiao Q; Xiao J; Niu C; Li Y; Zhang X; Zhou Z; Shu G; Yin G
Signal Transduct Target Ther; 2022 Jan; 7(1):3. PubMed ID: 34980884
[TBL] [Abstract][Full Text] [Related]
24. The Wnt signaling pathway in cancer.
Duchartre Y; Kim YM; Kahn M
Crit Rev Oncol Hematol; 2016 Mar; 99():141-9. PubMed ID: 26775730
[TBL] [Abstract][Full Text] [Related]
25. A positive role of cadherin in Wnt/β-catenin signalling during epithelial-mesenchymal transition.
Howard S; Deroo T; Fujita Y; Itasaki N
PLoS One; 2011; 6(8):e23899. PubMed ID: 21909376
[TBL] [Abstract][Full Text] [Related]
26. Targeting the WNT Signaling Pathway in Cancer Therapeutics.
Tai D; Wells K; Arcaroli J; Vanderbilt C; Aisner DL; Messersmith WA; Lieu CH
Oncologist; 2015 Oct; 20(10):1189-98. PubMed ID: 26306903
[TBL] [Abstract][Full Text] [Related]
27. Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics.
Tabatabai R; Linhares Y; Bolos D; Mita M; Mita A
Target Oncol; 2017 Oct; 12(5):623-641. PubMed ID: 28653295
[TBL] [Abstract][Full Text] [Related]
28. Wnt signaling in cancer.
Zhan T; Rindtorff N; Boutros M
Oncogene; 2017 Mar; 36(11):1461-1473. PubMed ID: 27617575
[TBL] [Abstract][Full Text] [Related]
29. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
30. Crosstalk between long non-coding RNAs and Wnt/β-catenin signalling in cancer.
Yang G; Shen T; Yi X; Zhang Z; Tang C; Wang L; Zhou Y; Zhou W
J Cell Mol Med; 2018 Apr; 22(4):2062-2070. PubMed ID: 29392884
[TBL] [Abstract][Full Text] [Related]
31. Targeting Tankyrase to Fight WNT-dependent Tumours.
Thorvaldsen TE
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
[TBL] [Abstract][Full Text] [Related]
32. Porcupine inhibitors: Novel and emerging anti-cancer therapeutics targeting the Wnt signaling pathway.
Shah K; Panchal S; Patel B
Pharmacol Res; 2021 May; 167():105532. PubMed ID: 33677106
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs.
Vallée A; Lecarpentier Y; Vallée JN
Cells; 2019 Jul; 8(7):. PubMed ID: 31311204
[TBL] [Abstract][Full Text] [Related]
34. Effects of anthocyanins on the prevention and treatment of cancer.
Lin BW; Gong CC; Song HF; Cui YY
Br J Pharmacol; 2017 Jun; 174(11):1226-1243. PubMed ID: 27646173
[TBL] [Abstract][Full Text] [Related]
35. Targeting the Wnt signalling pathway in cancer: prospects and perils.
Shaw HV; Koval A; Katanaev VL
Swiss Med Wkly; 2019 Sep; 149():w20129. PubMed ID: 31579927
[TBL] [Abstract][Full Text] [Related]
36. Mutations and mechanisms of WNT pathway tumour suppressors in cancer.
Bugter JM; Fenderico N; Maurice MM
Nat Rev Cancer; 2021 Jan; 21(1):5-21. PubMed ID: 33097916
[TBL] [Abstract][Full Text] [Related]
37. [Screening for Chemical Suppressors of the Wnt/β-catenin Signaling Pathway].
Nishiya N
Yakugaku Zasshi; 2017; 137(2):133-136. PubMed ID: 28154320
[TBL] [Abstract][Full Text] [Related]
38. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
39. Interplay between microRNAs and WNT/β-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer.
Ghahhari NM; Babashah S
Eur J Cancer; 2015 Aug; 51(12):1638-49. PubMed ID: 26025765
[TBL] [Abstract][Full Text] [Related]
40. Recent updates on Wnt signaling modulators: a patent review (2014-2020).
Goswami VG; Patel BD
Expert Opin Ther Pat; 2021 Nov; 31(11):1009-1043. PubMed ID: 34128760
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
